This personalized data can support discussion about protective supplementation timing, dosing, and monitoring intervalshelping optimize both weight-loss efficacy and hair health outcomes during GLP-1 treatment
doi: 10.1128/msystems.00001-18 [DOI] [PMC free article] [PubMed] [Google Scholar] 88.Dhamdhere G, Krishnamoorthy G, Zgurskaya HI
However, recommendations suggest to not use incretin based-therapies during pregnancy and to discontinue medication one to three months before pregnancy, depending on the particular drug [192] Therefore, the cessation of GLP-1 RAs before conception or in early pregnancy is associated with excessive gestational weight gain and a higher risk of adverse pregnancy outcomes, such as GDM, hypertensive disorders of pregnancy and preterm birth [193]
Moreover, because patients with T1D were excluded from studies looking at cardiovascular and renal outcomes with the use of GLP-1RA, it remains unknown whether those benefits observed in patients with T2D or obesity without T2D translate to the T1D population